Skip to content
value.today
Spruce Biosciences, Inc. logo

Spruce Biosciences, Inc.

SPRB
$130 Mmarket cap on Oct 26, 2026+10.9% since Jan 2024
Compare
World rank
#17,795
Revenue
—
For year ending December-2025
Net income
$-39 M
SEC filing
Employees
—

Spruce Biosciences, Inc. in brief

Spruce Biosciences, Inc. is a listed company in the Biotechnology industry, based in South San Francisco, California, USA. Its market value was $130 M on 26 October 2026, which makes it the 17,795th largest listed company in the world and the 3,383rd largest in the USA on this site. Javier B. Szwarcberg is its chief executive. Its shares trade under the symbol SPRB (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Spruce Biosciences, Inc.

Spruce Biosciences, Inc. is a Late Stage Biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It is having 15 employees as on 2020. The headquarters is in USA.

Spruce Biosciences, Inc. timeline

2 events, 2020
  1. 2020
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 9 October 2020; shares registered for exchange trading on 5 October 2020.

Events of Spruce Biosciences, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$152 M$305 M$457 M$609 M202120222023202420252026

World rank over time

▼ down 7,243 places since 2021
2021-01-01: #10595#10,59520212022-01-07: #23235#23,23520222022-12-25: #28429#28,42920222023-07-30: #22311#22,31120232024-01-05: #20614#20,61420242026-03-08: #10717#10,71720262026-08-01: #16194#16,19420262026-10-06: #17847#17,84720262026-10-26: #17838#17,8382026

Rank in USA: #2,652 (Jan 2021) · #4,493 (Jan 2022) · #5,174 (Dec 2022) · #4,323 (Jul 2023) · #3,594 (Jan 2024) · #2,097 (Mar 2026) · #3,239 (Aug 2026) · #3,349 (Oct 2026) · #3,387 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
3.1×
Free cash flow yield
-43.1%
Net margin
—
Operating margin
—
Return on equity
-91.7%
Liabilities / assets
19.8%
Net debt
$-49M
Revenue growth
-51.3%
R&D / revenue
945.4%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue —, net income $-13M—FY19Fiscal year ending Dec 2020: revenue —, net income $-30M—FY20Fiscal year ending Dec 2021: revenue —, net income $-42M—FY21Fiscal year ending Dec 2022: revenue —, net income $-46M—FY22Fiscal year ending Dec 2023: revenue $10M, net income $-48M$10MFY23Fiscal year ending Dec 2024: revenue $5M, net income $-53M$5MFY24Fiscal year ending Dec 2025: revenue —, net income $-39M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-37M$-39M—
Dec 2024$5M-51.3%$-56M$-53M-1080.2%
Dec 2023$10M—$-52M$-48M-474.9%
Dec 2022——$-47M$-46M—
Dec 2021——$-42M$-42M—
Dec 2020——$-29M$-30M—
Dec 2019——$-13M$-13M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-33M——$-50.83—
Dec 2024$-56M$0M$-56M$-96.40—
Dec 2023$-33M$0M$-33M$-1.24—
Dec 2022$-42M$0M$-42M$-1.96—
Dec 2021$-36M$0M$-36M$-1.81—
Dec 2020$-28M$0M$-28M$-4.93—
Dec 2019$-13M$0M$-13M$-17.12—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $1M, net income $-24M$1MDec ’24Three months to Mar 2025: revenue —, net income $-14M—Mar ’25Three months to Jun 2025: revenue —, net income $-2M—Jun ’25Three months to Sep 2025: revenue —, net income $-8M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-15M—Dec ’25Three months to Mar 2026: revenue —, net income $-12M—Mar ’26Three months to Jun 2026: revenue —, net income $-16M—Jun ’26Three months to Sep 2026: revenue —, net income $-24M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-24M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Spruce Biosciences, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-37 M
Net income
$-39 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$53 M
Total liabilities
$11 M
Total equity
$43 M

As of December-2025

Top 70 institutional investors in Spruce Biosciences, Inc.#

As of Sep 30, 2026
70 institutions held 1.9 M shares (about 67.3% of the shares outstanding) on Sep 30, 2026. The ten largest hold 45.9%. Source: SEC Form 13F filings, filed through Nov 17, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Spruce Biosciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1AIGH Capital Management LLC250,0000 (0.00%)8.70%$12 MNov 2, 2026
2Orbimed Advisors LLC242,800+42,800 (+21.40%)8.45%$12 MNov 16, 2026
3BlackRock, Inc.192,015+4,179 (+2.22%)6.68%$9 MNov 13, 2026
4Millennium Management LLC136,675-24,306 (-15.10%)4.76%$7 MNov 16, 2026
5Vanguard Capital Management LLC119,3310 (0.00%)4.15%$6 MNov 13, 2026
6Ikarian Capital, LLC101,356-20,000 (-16.48%)3.53%$5 MNov 16, 2026
7Citadel Advisors LLC90,610+38,705 (+74.57%)3.15%$4 MNov 16, 2026
8Geode Capital Management, LLC66,757-3,791 (-5.37%)2.32%$3 MNov 6, 2026
9Cable Car Capital, LP60,0000 (0.00%)2.09%$3 MNov 16, 2026
10State Street Corp59,032+8,582 (+17.01%)2.05%$3 MNov 12, 2026
11Alyeska Investment Group, L.P.51,671-30,000 (-36.73%)1.80%$3 MNov 16, 2026
12ADAR1 Capital Management, LLC51,646-16,071 (-23.73%)1.80%$3 MNov 16, 2026
13Point72 Asset Management, L.P.44,258+15,980 (+56.51%)1.54%$2 MNov 16, 2026
14Diadema Partners LP40,435+10,435 (+34.78%)1.41%$2 MNov 16, 2026
15Eversept Partners, LP39,840-160 (-0.40%)1.39%$2 MNov 16, 2026
16Carlyle Group Inc.38,6200 (0.00%)1.34%$2 MNov 6, 2026
17Boothbay Fund Management, LLC35,145-6,935 (-16.48%)1.22%$2 MNov 16, 2026
18Quinn Opportunity Partners LLC26,8100 (0.00%)0.93%$1 MNov 10, 2026
19Rosalind Advisors, Inc.26,517+6,517 (+32.58%)0.92%$1 MNov 16, 2026
20Knott David M Jr26,085+6,085 (+30.43%)0.91%$1 MNov 12, 2026
21ExodusPoint Capital Management, LP22,0000 (0.00%)0.77%$1 MNov 16, 2026
22Northern Trust Corp19,988-1,095 (-5.19%)0.70%$1 MNov 16, 2026
23XTX Topco Ltd19,690New0.69%$1 MNov 16, 2026
24Vanguard Fiduciary Trust Co19,077+716 (+3.90%)0.66%$1 MNov 13, 2026
25Ameriprise Financial Inc18,870+36 (+0.19%)0.66%$1 MNov 16, 2026
Show all 70: investors 26 to 70
Institutional investors 26 to 70 in Spruce Biosciences, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Vanguard Portfolio Management LLC17,180-1,316 (-7.12%)0.60%$1 MNov 13, 2026
27Balyasny Asset Management L.P.12,1380 (0.00%)0.42%$1 MNov 16, 2026
28Persistent Asset Partners Ltd10,334+2,657 (+34.61%)0.36%$1 MNov 13, 2026
29Engineers Gate Manager LP9,636New0.34%$0 MNov 16, 2026
30Morgan Stanley9,209+4,798 (+108.77%)0.32%$0 MNov 13, 2026
31Dimensional Fund Advisors LP8,788-25 (-0.28%)0.31%$0 MNov 4, 2026
32UBS Group AG7,910-15,471 (-66.17%)0.28%$0 MNov 10, 2026
33Jane Street Group, LLC7,549New0.26%$0 MNov 12, 2026
34State Board Of Administration Of Florida Retirement System7,1820 (0.00%)0.25%$0 MNov 13, 2026
35Bank of New York Mellon Corp6,819+40 (+0.59%)0.24%$0 MNov 5, 2026
36Goldman Sachs Group Inc6,766-25,582 (-79.08%)0.24%$0 MNov 16, 2026
37Charles Schwab Investment Management Inc6,072+176 (+2.99%)0.21%$0 MNov 16, 2026
38FMR LLC3,589+3,246 (+946.36%)0.12%$0 MNov 10, 2026
39Rhumbline Advisers3,453-66 (-1.88%)0.12%$0 MNov 10, 2026
40Nuveen, LLC2,501New0.09%$0 MNov 10, 2026
41Deutsche Bank AG\2,323-329 (-12.41%)0.08%$0 MNov 6, 2026
42New York State Common Retirement Fund1,9000 (0.00%)0.07%$0 MNov 17, 2026
43Tower Research Capital LLC (TRC)1,440+1,194 (+485.37%)0.05%$0 MNov 16, 2026
44Jpmorgan Chase & Co1,411+284 (+25.20%)0.05%$0 MNov 12, 2026
45MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.1,192-60 (-4.79%)0.04%$0 MNov 16, 2026
46Barclays PLC1,150+476 (+70.62%)0.04%$0 MNov 6, 2026
47Vanguard Global Advisers, LLC1,133+681 (+150.66%)0.04%$0 MNov 13, 2026
48Lion Point Capital, LP1,0000 (0.00%)0.03%$0 MNov 16, 2026
49Police & Firemen's Retirement System of New Jersey8640 (0.00%)0.03%$0 MNov 9, 2026
50BNP Paribas Financial Markets617+164 (+36.20%)0.02%$0 MNov 12, 2026
51Wells Fargo & Company/mn553-1,776 (-76.26%)0.02%$0 MNov 16, 2026
52PNC Financial Services Group, Inc.355New0.01%$0 MNov 6, 2026
53Royal Bank Of Canada315+149 (+89.76%)0.01%$0 MNov 16, 2026
54Russell Investments Group, Ltd.275+58 (+26.73%)0.01%$0 MNov 6, 2026
55Legal & General Group Plc2640 (0.00%)0.01%$0 MNov 16, 2026
56Ameritas Investment Partners, Inc.2470 (0.00%)0.01%$0 MNov 13, 2026
57SBI Securities Co., Ltd.2010 (0.00%)0.01%$0 MOct 22, 2026
58Pinnacle Wealth Planning Services, Inc.167New0.01%$0 MOct 27, 2026
59Citigroup Inc122-1,143 (-90.36%)0.00%$0 MNov 4, 2026
60Parkside Financial Bank & Trust97New0.00%$0 MOct 27, 2026
61GAMMA Investing LLC85New0.00%$0 MOct 8, 2026
62Sterling Capital Management LLC59+16 (+37.21%)0.00%$0 MOct 22, 2026
63Jones Financial Companies Lllp300 (0.00%)0.00%$0 MNov 13, 2026
64SJS Investment Consulting Inc.17New0.00%$0 MOct 26, 2026
65Caldwell Sutter Capital, Inc.130 (0.00%)0.00%$0 MNov 9, 2026
66Root Financial Partners, LLC8New0.00%$0 MOct 21, 2026
67Cassaday & Co Wealth Management LLC20 (0.00%)0.00%$0 MOct 27, 2026
68Allworth Financial LP1New0.00%$0 MNov 17, 2026
69Farther Finance Advisors, LLC1New0.00%$0 MOct 8, 2026
70Aster Capital Management (DIFC) Ltd1New0.00%$0 MNov 12, 2026

Mutual funds holding Spruce Biosciences, Inc.#

58 funds hold shares worth $16 M (about 10.5% of the company). Since their previous reports 53 added shares and 1 sold, buying $14 M net.
Mutual funds holding Spruce Biosciences, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.84,935$5 M3.0%<0.01%+1306%Jun 30, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors65,222$4 M2.3%<0.01%newJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.31,892$2 M1.1%<0.01%+168%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC29,694$1 M1.0%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors16,862$1 M0.59%<0.01%newJun 30, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors8,665$0 M0.30%0.03%newJun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors6,207$0 M0.22%<0.01%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.6,797$0 M0.24%<0.01%newJul 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC5,566$0 M0.19%<0.01%−2.0%May 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC4,827$0 M0.17%<0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Small Cap ETFDimensional Fund Advisors LP3,751$0 M0.13%<0.01%+192%Jul 31, 2026
🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC3,660$0 M0.13%<0.01%newJul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC2,837$0 M0.10%<0.01%newJun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC2,787$0 M0.10%<0.01%newJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation2,100$0 M0.07%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC1,920$0 M0.07%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC1,652$0 M0.06%<0.01%no changeMay 31, 2026
🇺🇸 U.S. Micro Cap PortfolioDimensional Fund Advisors LP1,968$0 M0.07%<0.01%+401%Jul 31, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.1,419$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.1,345$0 M0.05%<0.01%+1021%Jun 30, 2026
🇺🇸 Goldman Sachs Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.1,551$0 M0.05%<0.01%newJul 31, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.1,200$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.1,159$0 M0.04%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC1,299$0 M0.05%<0.01%newJul 31, 2026
🇺🇸 Tiff Multi-Asset FundTIFF Advisory Services, LLC832$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC817$0 M0.03%<0.01%no changeMay 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC768$0 M0.03%<0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC660$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC623$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC610$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC610$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC768$0 M0.03%<0.01%newJul 31, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS604$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC582$0 M0.02%0.01%newJun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC574$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Dimensional U.S. Core Equity 2 ETFDimensional Fund Advisors LP681$0 M0.02%<0.01%no changeJul 31, 2026
🇺🇸 NVIT GS Small Cap Equity Insights FundNATIONWIDE FUND ADVISORS493$0 M0.02%0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Variable Insurance Trust Small Cap Equity Insights FundGoldman Sachs Asset Management, L.P.479$0 M0.02%0.01%newJun 30, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.425$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.410$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC347$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC294$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Dimensional US Core Equity 1 ETFDimensional Fund Advisors LP371$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC318$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management247$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 U.S. Small Cap PortfolioDimensional Fund Advisors LP303$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC217$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.264$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS239$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC170$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 EQ/Morgan Stanley Small Cap Growth PortfolioEquitable Investment Management Group, LLC132$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC113$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC105$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Growth Index PortfolioPacific Life Fund Advisors LLC84$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.69$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC62$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC53$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC32$0 M<0.01%<0.01%newJun 30, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 58 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Spruce Biosciences, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
15
since
$9 K-$3.4 M$0Mar 2024: bought $0 (0 trades), sold $3.4 M (5 trades)Mar 24Oct 2025: bought $9 K (2 trades), sold $10 K (4 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Spruce Biosciences, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Javier B. SzwarcbergCHIEF EXECUTIVE OFFICER, DirectorGrant or award+266$4.530$1 K19,270Form 4
filed Javier B. SzwarcbergCHIEF EXECUTIVE OFFICER, DirectorGrant or award+4,690$4.530$21 K19,004Form 4
filed Javier B. SzwarcbergCHIEF EXECUTIVE OFFICER, DirectorOption exercise+1,480——14,478Form 4
filed Samir M. GharibPRESIDENT AND CFOOption exercise+496——8,112Form 4
filed Javier B. SzwarcbergCHIEF EXECUTIVE OFFICER, DirectorShares withheld for tax-752$80.67$61 K13,726Form 4
filed Samir M. GharibPRESIDENT AND CFOShares withheld for tax-178$80.67$14 K7,934Form 4
filed Samir M. GharibPRESIDENT AND CFOOption exercise+513——8,447Form 4
filed Javier B. SzwarcbergCHIEF EXECUTIVE OFFICER, DirectorOption exercise+1,196——14,922Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Spruce Biosciences, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
531,380
38.7% of shares · 6.95 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-6.54 reverse split

Trading halts

  • 2025-10-07 14:56 UTC, code LUDP, resumed 15:01 UTC
  • 2025-10-07 13:48 UTC, code LUDP, resumed 13:53 UTC
  • 2025-10-07 13:32 UTC, code LUDP, resumed 13:37 UTC
  • 2025-10-06 19:48 UTC, code LUDP, resumed 20:00 UTC
  • 2025-10-06 19:27 UTC, code LUDP, resumed 19:47 UTC

Fails to deliver

  • : 190 shares at $45.15
  • : 106 shares at $40.40
  • : 990 shares at $38.98
  • : 713 shares at $45.42
  • : 95 shares at $47.27

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Spruce Biosciences, Inc. scorecard#

Passes 3 of the 15 checks that could be worked out: strongest in financial health (3 of 5), weakest in valuation (0 of 4). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' median3.0×Price to book 3.0× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-43.1%Free cash flow is -43.1% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-50.83 vs -96.40Diluted EPS -50.83 in fiscal 2025 against -96.40 the year before (report's currency).
    • ✗Net income higher than five years earlier-$39 M-$39 M in fiscal 2025 against -$30 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$39 MNet income -$39 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-109.2%-109.2% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health3 of 5
    • ✓Short-term assets cover short-term liabilities5.2×Current ratio 5.16 at the end of fiscal 2025.
    • ✓Debt below equity0.0×Debt to equity 0.00 at the end of fiscal 2025.
    • ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $49 M at the end of fiscal 2025.
    • ✗Operating income covers interest five times-405.7×Operating income -405.7 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year39.5%Diluted shares up 39.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Spruce Biosciences, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Spruce Biosciences, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Revenue04.9100———
Research and development20464935312411
General and administrative17151312115.62.3
Operating expenses37616247422913
Operating income−37−56−52−47−42−29−13
Interest expense and finance costs0.10.30.50.40.30.30.1
Other non-operating income (expense)————0.10.20.1
Income tax0000000
Net income including minority interests−39−53−48−46−42−30−13
Net income attributable to shareholders−39−53−48−46−42−30−13
Earnings per share, basic-50.83-96.40r-1.24-1.96-1.81-4.93-17.12
Earnings per share, diluted-50.83-96.40r-1.24-1.96-1.81-4.93-17.12
Shares, weighted average (basic)0.80.6r392423——
Shares, weighted average (diluted)0.80.6r3924236.00.8
Balance sheet
Cash and cash equivalents49399624431573.9
Short-term investments——05546——
Receivables———0———
Other current assets2.92.32.01.20.4r0.30.5
Current assets524410284921604.7
Property, plant and equipment————0.10.1—
Right-of-use (leased) assets———1.41.51.8—
Long-term investments———032——
Total assets5345104861261634.7
Accounts payable0.91.33.31.42.83.61.9
Debt due within a year01.61.61.602.61.3
Current liabilities101524128.99.84.3
Long-term debt00.11.73.34.91.93.2
Lease liabilities (non-current)0.40.71.01.31.31.7—
Total liabilities1116271715137.5
Retained earnings−289−250−197−149−103−61−31
Shareholders' equity43297768111149−31
Total liabilities and equity5345104861261634.7
Shares outstanding1.40.6r412423230.8
Cash-flow statement
Depreciation and amortization0.00.00.10.10.10.00.0
Share-based compensation2.65.34.63.64.00.80.2
Cash from operating activities−33−56−33−42−36−28−13
Capital expenditure—0−0.0−0.0−0.1−0.1−0.0
Cash from investing activities—05624−79−0.1−0.0
Debt issued———05.0—4.5
Debt repaid−2.1−1.6−1.60−4.8——
Cash from financing activities43−1.649−0.20.618112
Report10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Spruce Biosciences, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$2.9 M
Javier Szwarcberg
Other top executives, average
$1.3 M
the CEO earned 2.3× this
$100 invested is now
$40
Spruce Biosciences, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Javier Szwarcberg$2.9 M$4.2 M$1.3 M$40
2024Javier Szwarcberg$1.5 M−$993 K$1.0 M$14

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Spruce Biosciences, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling

Delisting notice 3 · Restructuring 1 · Directors and officers 6 · Material agreement 5 · Agreement ended 2 · New debt 1 · Unregistered share sale 3 · Shareholder rights changed 2 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 12

Spruce Biosciences, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Directors and officers8-K
Shareholder vote8-K
Results announced8-K
Material agreement8-K
Agreement ended8-K
Directors and officersMaterial agreementAgreement endedResults announced8-K
Material agreementNew debtUnregistered share saleResults announced8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Shareholder rights changedBylaws or fiscal year changedShareholder vote8-K
Delisting notice8-K
Material agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Delisting noticeRestructuring8-K
Results announced8-K
Results announced8-K
Directors and officers8-K
Results announced8-K
Delisting notice8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 9, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Spruce Biosciences, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2025$50 MPrivate placement after listing$50 to $250 million21equity, optionsSEC
Feb 2023$54 MPrivate placement after listing$50 to $250 million20equity, optionsSEC
Feb 2020$88 MNo. 1$50 to $250 million11equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Spruce Biosciences, Inc.#

1 labor condition applications certified in fiscal 2025 for 1 positions, at a median wage of $266 K a year.

Certified, FY2025
1
#1,954 among companies on value.today
Worker positions
1
Median wage offered
$266 K
a year, full-time
Applications filed
1
Spruce Biosciences, Inc.: most frequent H-1B job titles in fiscal 2025
Job titlePositionsMedian wage offered
Senior Director of CMC OperationsNatural Sciences Managers1$266 K

Where: South San Francisco, CA 1

Spruce Biosciences, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202511$266 K1
FY202211$218 K1
FY202011$210 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Spruce Biosciences, Inc.

Layoffs at Spruce Biosciences, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2024–2025
Latest
—
2025-04-21
Spruce Biosciences, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025············—
2024············—
Spruce Biosciences, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How Spruce Biosciences, Inc. compares in Biotechnology

  • Market cap$130 M · higher than 40% of 726
  • Revenue growth-51.3% · higher than 17% of 438
  • Price / book3.0× · lower than 48% of 534
  • FCF yield-43.1% · higher than 27% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Spruce Biosciences, Inc.🇺🇸$130 M——-51.3%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Spruce Biosciences, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Spruce Biosciences, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Spruce Biosciences, Inc.? Suggest a correction